Biocon listed on Dow Jones Sustainability Emerging Markets Index
Bengaluru: Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced it has been selected to be in the Dow Jones Sustainability Index (DJSI) in the Emerging Markets (EM) category for its progressive Environmental, Social and Governance (ESG) practices.
Biocon made a formal submission for Corporate Sustainability Assessment for its listing on the DJSI for the first time this year and made it to the DJSI EM Index with a Total Sustainability Score of 45 as against an industry average of 18, achieving a 93rd percentile position.
It is among the Top 15 companies from India and one of the 12 companies from the Pharmaceuticals, Biotechnology & Life Sciences sectors to be featured in the index for 2021. A total of 360 Indian companies were invited to participate in DJSI in 2021.
"Sustainability has been among Biocon's topmost priorities since inception and both Biocon and Biocon Biologics are committed to provide insights into their ESG performance to their stakeholders," the release said.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said, "Our business purpose is focused on delivering health equity by providing affordable access to life saving and essential medicines to patients across the world. Our entry in the DJSI Emerging Markets Index is a testimony to our responsible and sustainable business practices and our philosophy of putting equity and equality at the center of everything we do. The DJSI Index provides an important yardstick for Biocon and Biocon Biologics to measure sustainability performance and continuously improve reporting on ESG to address the growing interest of our global stakeholders."
Read also: Biocon Biologics, Viatris to offer Insulin Glargine by Walgreens Prescription Savings Club
Biocon Limited is an innovation-led global biopharmaceuticals company headquartered in Bangalore. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.
